Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
ABBOTT PARK, Ill., July 16, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2026.
"Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
SECOND-QUARTER BUSINESS OVERVIEW
Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical Devices
U.S.
5,216
871
1,660
—
2,680
International
7,377
1,273
1,432
1,499
3,173
Total reported
12,593
2,144
3,092
1,499
5,853
% Change vs. 2Q25
U.S.
22.0
(9.0)
104.8
n/a
7.0
International
7.5
1.4
5.1
8.4
10.7
Total reported
13.0
(3.1)
42.3
8.4
9.0
Total reported excl. foreign exchange impact
12.2
(3.6)
41.3
8.7
7.9
Comparable sales growth
4.8
(3.6)
2.9
8.7
8.4
U.S.
3.5
(9.0)
4.0
n/a
8.0
International
5.8
0.6
1.6
8.7
8.7
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical Devices
U.S.
9,490
1,715
2,565
—
5,203
International
14,267
2,446
2,707
2,925
6,189
Total reported
23,757
4,161
5,272
2,925
11,392
% Change vs. 1H25
U.S.
12.4
(10.3)
52.5
n/a
7.4
International
9.3
—
6.4
10.7
14.2
Total reported
10.5
(4.5)
24.7
10.7
11.0
Total reported excl. foreign exchange impact
8.2
(5.6)
22.4
8.9
8.0
Comparable sales growth
4.3
(5.6)
2.4
8.9
8.4
U.S.
3.0
(10.3)
3.0
n/a
8.3
International
5.3
(1.9)
1.6
8.9
8.5
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.
Nutrition
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Pediatric
Adult
U.S.
871
525
346
International
1,273
500
773
Total reported
2,144
1,025
1,119
% Change vs. 2Q25
U.S.
(9.0)
(10.7)
(6.4)
International
1.4
7.3
(2.0)
Total reported
(3.1)
(2.7)
(3.4)
Total reported excl. foreign exchange impact
(3.6)
(3.1)
(4.0)
Comparable sales growth
(3.6)
(3.1)
(4.0)
U.S.
(9.0)
(10.7)
(6.4)
International
0.6
6.4
(2.8)
Worldwide Nutrition sales decreased 3.1 percent on a reported basis and 3.6 percent on a comparable basis in the second quarter.
Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of new products, are contributing to improving performance. Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Pediatric
Adult
U.S.
1,715
1,036
679
International
2,446
942
1,504
Total reported
4,161
1,978
2,183
% Change vs. 1H25
U.S.
(10.3)
(11.9)
(7.8)
International
—
2.4
(1.5)
Total reported
(4.5)
(5.6)
(3.5)
Total reported excl. foreign exchange impact
(5.6)
(6.4)
(4.9)
Comparable sales growth
(5.6)
(6.4)
(4.9)
U.S.
(10.3)
(11.9)
(7.8)
International
(1.9)
0.7
(3.5)
Diagnostics*
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Core Laboratory
Cancer Diagnostics
Rapid/Molecular
Diagnostics
U.S.
1,660
377
890
393
International
1,432
1,041
29
362
Total reported
3,092
1,418
919
755
% Change vs. 2Q25
U.S.
104.8
7.5
n/a
(14.5)
International
5.1
3.4
n/a
2.0
Total reported
42.3
4.4
n/a
(7.3)
Total reported excl. foreign exchange impact
41.3
3.2
n/a
(8.0)
Comparable sales growth
2.9
3.2
13.3
(8.0)
U.S.
4.0
7.5
13.3
(14.5)
International
1.6
1.7
13.8
0.5
Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter.
Worldwide Core Laboratory Diagnostics results were driven by strong growth in the U.S. and Latin America.
Rapid and Molecular Diagnostics results reflect lower sales of respiratory virus tests compared to the prior year.
Cancer Diagnostics results were driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users. Results in the quarter also reflect contributions to growth from the precision oncology and international businesses.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Core Laboratory
Cancer Diagnostics
Rapid/Molecular
Diagnostics
U.S.
2,565
724
983
858
International
2,707
1,966
32
709
Total reported
5,272
2,690
1,015
1,567
% Change vs. 1H25
U.S.
52.5
6.0
n/a
(14.1)
International
6.4
6.1
n/a
2.4
Total reported
24.7
6.1
n/a
(7.4)
Total reported excl. foreign exchange impact
22.4
3.2
n/a
(8.8)
Comparable sales growth
2.4
3.2
13.3
(8.8)
U.S.
3.0
6.0
13.2
(14.1)
International
1.6
2.2
16.5
(1.1)
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.
Established Pharmaceuticals
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Key Emerging
Markets
Other
U.S.
—
—
—
International
1,499
1,164
335
Total reported
1,499
1,164
335
% Change vs. 2Q25
U.S.
n/a
n/a
n/a
International
8.4
9.8
3.7
Total reported
8.4
9.8
3.7
Total reported excl. foreign exchange impact
8.7
10.7
2.1
Comparable sales growth
8.7
10.7
2.1
U.S.
n/a
n/a
n/a
International
8.7
10.7
2.1
Established Pharmaceuticals sales increased 8.4 percent on a reported basis and 8.7 percent on a comparable basis in the second quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Key Emerging
Markets
Other
U.S.
—
—
—
International
2,925
2,253
672
Total reported
2,925
2,253
672
% Change vs. 1H25
U.S.
n/a
n/a
n/a
International
10.7
11.3
8.6
Total reported
10.7
11.3
8.6
Total reported excl. foreign exchange impact
8.9
10.1
4.9
Comparable sales growth
8.9
10.1
4.9
U.S.
n/a
n/a
n/a
International
8.9
10.1
4.9
Medical Devices
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Rhythm
Management
Electro-
physiology*
Heart
Failure
Vascular
Structural
Heart*
Neuro-
modulation
Diabetes
Care
U.S.
2,680
377
420
313
294
225
189
862
International
3,173
366
441
88
509
372
71
1,326
Total reported
5,853
743
861
401
803
597
260
2,188
% Change vs. 2Q25
U.S.
7.0
10.7
15.9
10.9
3.9
(9.8)
(2.1)
8.6
International
10.7
10.0
12.3
3.0
7.5
12.1
14.7
11.7
Total reported
9.0
10.4
14.0
9.0
6.1
2.7
2.0
10.5
Total reported excl. foreign exchange impact
7.9
9.5
13.4
8.7
5.1
1.7
1.2
9.0
Comparable sales growth
8.4
9.5
13.4
8.7
5.1
5.7
1.2
9.0
U.S.
8.0
10.7
15.9
10.9
3.9
(0.9)
(2.1)
8.6
International
8.7
8.3
11.1
1.3
5.8
10.2
11.3
9.2
Worldwide Medical Devices sales increased 9.0 percent on a reported basis and 8.4 percent on a comparable basis in the second quarter.
Sales growth in the quarter was led by low-teens growth in Electrophysiology and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure.
In Diabetes Care, sales of continuous glucose monitors grew 11.0 percent on a reported basis and 9.5 percent on a comparable basis.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Rhythm
Management
Electro-
physiology*
Heart
Failure
Vascular
Structural
Heart*
Neuro-
modulation
Diabetes
Care
U.S.
5,203
716
798
605
585
449
366
1,684
International
6,189
711
851
185
995
726
137
2,584
Total reported
11,392
1,427
1,649
790
1,580
1,175
503
4,268
% Change vs. 1H25
U.S.
7.4
11.1
14.8
11.1
6.2
(9.6)
(0.7)
9.2
International
14.2
15.9
15.7
13.5
8.7
18.1
20.4
14.0
Total reported
11.0
13.4
15.3
11.7
7.7
5.7
4.3
12.1
Total reported excl. foreign exchange impact
8.0
10.9
13.0
10.4
5.0
2.6
2.6
8.2
Comparable sales growth
8.4
10.9
13.0
10.4
5.0
6.2
2.6
8.2
U.S.
8.3
11.1
14.8
11.1
6.2
(2.2)
(0.7)
9.2
International
8.5
10.7
11.2
7.8
4.3
12.4
13.2
7.5
*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.
Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% 1.
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60.
Abbott projects third-quarter 2026 adjusted diluted earnings per share of $1.38 to $1.46.
Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.
Abbott Declares 410 th Consecutive Quarterly Dividend
On June 12, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.
Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Second Quarter Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
2Q26
2Q25
% Change
Net Sales
$12,593
$11,142
13.0
Cost of products sold, excluding amortization expense
5,325
4,854
9.7
Amortization of intangible assets
658
420
56.8
Research and development
892
725
22.9
Selling, general, and administrative
4,025
3,091
30.3
Total Operating Cost and Expenses
10,900
9,090
19.9
Operating Earnings
1,693
2,052
(17.5)
Interest expense, net
299
50
n/m
Net foreign exchange (gain) loss
4
(11)
n/m
Other (income) expense, net
(134)
(137)
(2.5)
Earnings before taxes
1,524
2,150
(29.1)
Taxes on Earnings
596
371
60.8
1)
Net Earnings
$928
$1,779
(47.8)
Net Earnings excluding Specified Items, as described below
$2,290
$2,213
3.5
2)
Diluted Earnings per Common Share
$0.53
$1.01
n/m
Diluted Earnings per Common Share, excluding Specified Items, as described below
$1.31
$1.26
4.0
2)
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options
1,743
1,751
NOTES:
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following section.
1)
2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)
2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.362 billion, or $0.78 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
First Half Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
1H26
1H25
% Change
Net Sales
$23,757
$21,500
10.5
Cost of products sold, excluding amortization expense
10,215
9,322
9.6
Amortization of intangible assets
1,080
840
28.5
Research and development
1,659
1,441
15.1
Selling, general, and administrative
7,765
6,152
26.2
Total Operating Cost and Expenses
20,719
17,755
16.7
Operating Earnings
3,038
3,745
(18.9)
Interest expense, net
367
99
n/m
Net foreign exchange (gain) loss
(9)
(18)
n/m
Other (income) expense, net
(293)
(264)
10.6
Earnings before taxes
2,973
3,928
(24.3)
Taxes on earnings
968
824
17.5
1)
Net Earnings
$2,005
$3,104
n/m
Net Earnings excluding Specified Items, as described below
$4,312
$4,132
4.4
2)
Diluted Earnings per Common Share
$1.14
$1.77
n/m
Diluted Earnings per Common Share,
excluding Specified Items, as described below
$2.46
$2.35
4.7
2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
1,745
1,749
NOTES:
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following section.
1)
2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)
2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.307 billion, or $1.32 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, restructuring, and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Second Quarter Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
2Q26
As
Reported
(GAAP)
Specified
Items
As
Adjusted
Intangible Amortization
$ 658
$ (658)
$ —
Gross Margin
6,610
697
7,307
R&D
892
(25)
867
SG&A
4,025
(428)
3,597
Other (income) expense, net
(134)
(27)
(161)
Earnings before taxes
1,524
1,177
2,701
Taxes on Earnings
596
(185)
411
Net Earnings
928
1,362
2,290
Diluted Earnings per Share
$ 0.53
$ 0.78
$ 1.31
Specified items reflect intangible amortization expense of $658 million and other net expenses of $519 million associated with acquisitions, legal reserves, investment impairments, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
2Q25
As
Reported
(GAAP)
Specified
Items
As
Adjusted
Intangible Amortization
$ 420
$ (420)
$ —
Gross Margin
5,868
478
6,346
R&D
725
(20)
705
SG&A
3,091
(1)
3,090
Other (income) expense, net
(137)
(1)
(138)
Earnings before taxes
2,150
500
2,650
Taxes on Earnings
371
66
437
Net Earnings
1,779
434
2,213
Diluted Earnings per Share
$ 1.01
$ 0.25
$ 1.26
Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
First Half Ended June 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
1H26
As
Reported
(GAAP)
Specified
Items
As
Adjusted
Intangible Amortization
$ 1,080
$ (1,080)
$ —
Gross Margin
12,462
1,129
13,591
R&D
1,659
(49)
1,610
SG&A
7,765
(901)
6,864
Other (income) expense, net
(293)
(34)
(327)
Earnings before taxes
2,973
2,113
5,086
Taxes on Earnings
968
(194)
774
Net Earnings
2,005
2,307
4,312
Diluted Earnings per Share
$ 1.14
$ 1.32
$ 2.46
Specified items reflect intangible amortization expense of $1.080 billion and other net expenses of $1.033 billion associated with restructuring actions, acquisitions, legal reserves, investment impairments, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
1H25
As
Reported
(GAAP)
Specified
Items
As
Adjusted
Intangible Amortization
$ 840
$ (840)
$ —
Gross Margin
11,338
926
12,264
R&D
1,441
(47)
1,394
SG&A
6,152
(11)
6,141
Other (income) expense, net
(264)
(36)
(300)
Earnings before taxes
3,928
1,020
4,948
Taxes on Earnings
824
(8)
816
Net Earnings
3,104
1,028
4,132
Diluted Earnings per Share
$ 1.77
$ 0.58
$ 2.35
Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
A reconciliation of the second-quarter tax rates for 2026 and 2025 is shown below:
2Q26
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$ 1,524
$ 596
39.1 %
1)
Specified items
1,177
(185)
Excluding specified items
$ 2,701
$ 411
15.2 %
2Q25
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$ 2,150
$ 371
17.3 %
2)
Specified items
500
66
Excluding specified items
$ 2,650
$ 437
16.5 %
1)
2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below:
1H26
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$ 2,973
$ 968
32.5 %
3)
Specified items
2,113
(194)
Excluding specified items
$ 5,086
$ 774
15.2 %
1H25
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$ 3,928
$ 824
21.0 %
4)
Specified items
1,020
(8)
Excluding specified items
$ 4,948
$ 816
16.5 %
3)
2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
4)
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Second Quarter Ended June 30, 2026 and 2025
($ in millions)
(unaudited)
2Q26
2Q25
% Change vs. 2Q25
Non-GAAP
Abbott
Reported
Foreign
exchange
Comparable
Revenue
Abbott
Reported
Impact of
acquisition (a)
Impact
of multi-year
agreement (b)
Comparable
Revenue
Reported
Comparable
Total Company
12,593
(86)
12,507
11,142
811
(22)
11,931
13.0
4.8
U.S.
5,216
—
5,216
4,276
786
(22)
5,040
22.0
3.5
Intl
7,377
(86)
7,291
6,866
25
—
6,891
7.5
5.8
Total Diagnostics
3,092
(22)
3,070
2,173
811
—
2,984
42.3
2.9
U.S.
1,660
—
1,660
811
786
—
1,597
104.8
4.0
Intl
1,432
(22)
1,410
1,362
25
—
1,387
5.1
1.6
Total Cancer Diagnostics
919
—
919
—
811
—
811
n/a
13.3
U.S.
890
—
890
—
786
—
786
n/a
13.3
Intl
29
—
29
—
25
—
25
n/a
13.8
Total Medical Devices
5,853
(57)
5,796
5,369
—
(22)
5,347
9.0
8.4
U.S.
2,680
—
2,680
2,503
—
(22)
2,481
7.0
8.0
Intl
3,173
(57)
3,116
2,866
—
—
2,866
10.7
8.7
Total Structural Heart*
597
(6)
591
581
—
(22)
559
2.7
5.7
U.S.
225
—
225
249
—
(22)
227
(9.8)
(0.9)
Intl
372
(6)
366
332
—
—
332
12.1
10.2
*
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 were moved from Structural Heart to Electrophysiology.
a)
The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
b)
Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
First Half Ended June 30, 2026 and 2025
($ in millions)
(unaudited)
1H26
1H25
% Change vs. 1H25
Non-GAAP
Abbott
Reported
Impact of
acquisition (a)
Impact
of multi-year
agreement (b)
Foreign
exchange
Comparable
Revenue
Abbott
Reported
Impact of
acquisition (a)
Impact
of multi-year
agreement (b)
Comparable
Revenue
Reported
Comparable
Total Company
23,757
706
(8)
(500)
23,955
21,500
1,518
(46)
22,972
10.5
4.3
U.S.
9,490
681
(8)
—
10,163
8,444
1,470
(46)
9,868
12.4
3.0
Intl
14,267
25
—
(500)
13,792
13,056
48
—
13,104
9.3
5.3
Total Diagnostics
5,272
706
—
(98)
5,880
4,227
1,518
—
5,745
24.7
2.4
U.S.
2,565
681
—
—
3,246
1,682
1,470
—
3,152
52.5
3.0
Intl
2,707
25
—
(98)
2,634
2,545
48
—
2,593
6.4
1.6
Total Cancer Diagnostics
1,015
706
—
(1)
1,720
—
1,518
—
1,518
n/a
13.3
U.S.
983
681
—
—
1,664
—
1,470
—
1,470
n/a
13.2
Intl
32
25
—
(1)
56
—
48
—
48
n/a
16.5
Total Medical Devices
11,392
—
(8)
(306)
11,078
10,264
—
(46)
10,218
11.0
8.4
U.S.
5,203
—
(8)
—
5,195
4,842
—
(46)
4,796
7.4
8.3
Intl
6,189
—
—
(306)
5,883
5,422
—
—
5,422
14.2
8.5
Total Structural Heart*
1,175
—
(8)
(35)
1,132
1,112
—
(46)
1,066
5.7
6.2
U.S.
449
—
(8)
—
441
497
—
(46)
451
(9.6)
(2.2)
Intl
726
—
—
(35)
691
615
—
—
615
18.1
12.4
*
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.
a)
The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
b)
Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2026
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$ 32
$ 4
$ 658
$ 3
$ 697
R&D
(10)
—
—
(15)
(25)
SG&A
(42)
(1)
—
(385)
(428)
Other (income) expense, net
1
(1)
—
(27)
(27)
Earnings before taxes
$ 83
$ 6
$ 658
$ 430
1,177
Taxes on Earnings (d)
(185)
Net Earnings
$ 1,362
Diluted Earnings per Share
$ 0.78
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)
Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.
c)
Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)
Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2025
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$ 1
$ 55
$ 420
$ 2
$ 478
R&D
—
(7)
—
(13)
(20)
SG&A
(3)
1
—
1
(1)
Other (income) expense, net
(1)
—
—
—
(1)
Earnings before taxes
$ 5
$ 61
$ 420
$ 14
500
Taxes on Earnings (d)
66
Net Earnings
$ 434
Diluted Earnings per Share
$ 0.25
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)
Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)
Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2026
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$ 34
$ 11
$ 1,080
$ 4
$ 1,129
R&D
(11)
(10)
—
(28)
(49)
SG&A
(486)
(34)
—
(381)
(901)
Other (income) expense, net
(1)
(3)
—
(30)
(34)
Earnings before taxes
$ 532
$ 58
$ 1,080
$ 443
2,113
Taxes on Earnings (d)
(194)
Net Earnings
$ 2,307
Diluted Earnings per Share
$ 1.32
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)
Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.
c)
Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)
Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2025
(in millions, except per share data)
(unaudited)
Acquisition or
Divestiture-
related (a)
Restructuring
and Cost
Reduction
Initiatives (b)
Intangible
Amortization
Other (c)
Total
Specifieds
Gross Margin
$ 1
$ 81
$ 840
$ 4
$ 926
R&D
(1)
(23)
—
(23)
(47)
SG&A
(6)
(6)
—
1
(11)
Other (income) expense, net
(25)
—
—
(11)
(36)
Earnings before taxes
$ 33
$ 110
$ 840
$ 37
1,020
Taxes on Earnings (d)
(8)
Net Earnings
$ 1,028
Diluted Earnings per Share
$ 0.58
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)
Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.
d)
Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
SOURCE Abbott